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Abstract: We demonstrate that RuII(CO)2–protein complexes,
formed by the reaction of the hydrolytic decomposition
products of [fac-RuCl(k2-H2NCH2CO2)(CO)3] (CORM-3)
with histidine residues exposed on the surface of proteins,
spontaneously release CO in aqueous solution, cells, and mice.
CO release was detected by mass spectrometry (MS) and
confocal microscopy using a CO-responsive turn-on fluores-
cent probe. These findings support our hypothesis that plasma
proteins act as CO carriers after in vivo administration of
CORM-3. CO released from a synthetic bovine serum albumin
(BSA)–RuII(CO)2 complex leads to downregulation of the
cytokines interleukin (IL)-6, IL-10, and tumor necrosis factor
(TNF)-a in cancer cells. Finally, administration of BSA–
RuII(CO)2 in mice bearing a colon carcinoma tumor results in
enhanced CO accumulation at the tumor. Our data suggest the
use of RuII(CO)2–protein complexes as viable alternatives for
the safe and spatially controlled delivery of therapeutic CO
in vivo.
Carbon monoxide (CO)-releasing molecules (CORMs)
have been shown to mimic the therapeutic effect of gaseous
CO in several biological settings.[1,2] Most CORMs described
to date are metal carbonyl complexes.[3] Examples include
esterase- and phosphatase-triggered Fe-based complexes,[4]
photoactivated complexes,[5] vitamin B12 Re-based com-
plexes,[6] or liver-targeted [Mo(CO)3(CNR)3]
[7] and [RuCl2-
thiogalactopyranoside(CO)3]
[8] complexes. However, it has
been [fac-RuCl(k2-H2NCH2CO2)(CO)3] (CORM-3) that has
attracted most interest due to its therapeutic benefit in animal
models of cardiovascular disease, organ transplantation, and
acute lung, kidney, and liver injury.[1–2] Nevertheless, there are
a number of issues that hinder the clinical development of
CORM-3. Its instability in water leads to a half-life in human
plasma of only 3.6 min.[9,10] Also, although CORM-3 was
initially thought to be a fast CO releaser as assessed by the
deoxymyoglobin carbonylation assay, it has been recently
demonstrated that it is in fact the reducing agent sodium
dithionite used in the assay that promotes the release of CO
from CORM-3.[11] This is consistent with the fact that when
CORM-3 is dissolved in buffered aqueous solution in a closed
vial, only CO2 can be detected in the headspace as analyzed
by gas chromatography (GC).[10,12,13] This can be explained by
a water–gas shift reaction mechanism, in which one CO is first
attacked by water resulting in the generation and release of
CO2 (Figure 1a).
[14] In addition, we[13] and others[15] have
shown that complexes of the general formula [RuL3(CO)3]
2+
(L= ligand) including CORM-3 react rapidly with proteins to
form di- and monocarbonyl RuII–protein adducts. Together,
these examples underline the need for a clear understanding
of how the in vivo administration of CORM-3 leads to CO
release. The elucidation of the CO release profile of CORM-3
in vivo will help guiding the design and synthesis of prodrugs
with improved CO release properties and efficacy.
In the present study we set ourselves to elucidate how
CORM-3 leads to CO release in vivo. By exploring the
chemical instability of CORM-3 in water, we developed
a ready method for histidine (His) metalation of proteins.
Access to synthetic RuII(CO)2–protein complexes allowed to
discover that such metalloproteins spontaneously release CO
in aqueous solution, cells, and mice. To date, it has remained
unclear how exactly the administration of CORM-3 in vivo
leads to CO release. In this work, we unequivocally demon-
strate for the first time that metalloproteins, formed from the
reaction of the hydrolytic decomposition products of CORM-
3 with His residues exposed on the surface of proteins, are
responsible for the in vivo release of CO and not CORM-3
itself.
We began by building a chemically defined dicarbonyl
RuII–protein complex. Access to such a defined protein
complex would allow a detailed evaluation of CO release by
mass spectrometry (MS) in buffered aqueous solution. We
chose hen egg white lysozyme (HEWL) as a model protein
due to its single-surface-exposed His at position 15, which has
already been shown to react selectively with the [Ru(CO)2]
2+
fragment derived from CORM-3 exposure to water.[13] This
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fragment is most likely the result of the loss of a chloride ion,
a glycinate, and one equivalent of CO2, after attack of water at
one CO (Figure 1a). Reaction of HEWL with 50 equivalents
of CORM-3 in phosphate-buffered saline (PBS) at pH 7.4 for
1 hour at room temperature produced a single peak with
a mass of 14463 Da corresponding to the successful metal-
ation of HEWL as detected by liquid chromatography MS
(LC-MS; Figure 1b). This is consistent with the capture of
[Ru(CO)2]
2+ by His and is in agreement with X-ray diffraction
analysis data of HEWL crystals soaked with CORM-3, which
showed that the highest occupation site contains the
[Ru(CO)2]
2+ fragment bound to His15.[13] The stability of
the purified synthetic HEWL–RuII(CO)2 complex was sub-
sequently evaluated in buffered aqueous solution by LC-MS.
After 2 h, a new peak with a mass of 14435 Da could already
be observed (Figure 1c). The new peak, corresponding to the
loss of a 28 Da unit of the initial mass of the protein complex,
became the main protein peak (> 95% conversion) after 4 h.
The loss of a 28 Da unit is consistent with decarbonylation
and conversion of HEWL–RuII(CO)2 to HEWL–Ru
II(CO)
with consequent release of CO. This result
suggests that CORM-3 does not liberate
CO spontaneously. Instead, CO is released
from the protein complexes formed from
the reaction of decomposition products of
CORM-3 with His residues exposed on
proteins in aqueous solution.
Our MS data, however, does not
exclude the hypothesis that the CO lost
from HEWL–RuII(CO)2 could also be
liberated as CO2 formed through
a water–gas shift reaction (Figure 1a).[14]
Thus, to unequivocally demonstrate that
dicarbonyl RuII–protein complexes carry
and release CO, we decided to apply the
CORM-3 His metalation strategy to albu-
min as a model carrier protein and use
a CO-responsive fluorescent probe to
detect CO. Albumin is the most abundant
protein in plasma and has been suggested
as a possible carrier of CORM-3 frag-
ments in vivo.[13,15,16] We started by mod-
ifying bovine serum albumin (BSA) using
CORM-3 as a metalation reagent under
conditions identical to those previously
applied for the His metalation of HEWL.
Treatment of BSA with 50 equivalents of
CORM-3 at room temperature for 1 hour
in PBS pH 7.4 yielded a BSA complex
with higher m/z in > 95% conversion as
assessed using nondenaturing nano-elec-
trospray ionization MS (native MS). This
corresponds to an average of seven modi-
fied His residues from a total of 16 per
BSA molecule (Figure 2a). To detect CO
release from the synthesized dicarbonyl
RuII–BSA complex we employed the CO-
selective turn-on fluorescent probe COP-
1 reported by Chang and co-workers.[17]
COP-1 selectively reacts with CO through a palladium-
mediated carbonylation reaction and was synthesized accord-
ing to the literature.[17] First, we performed a CO release
analysis in buffered aqueous solution at physiological pH
(PBS pH 7.4) and were pleased to observe that CO released
from the BSA–RuII(CO)2 complex triggered a robust fluo-
rescence turn-on response (sevenfold increase within
120 min; Figure 2b). In the absence of CO, COP-1 is only
weakly fluorescent (see Figure S1 in the Supporting Informa-
tion, SI). Next, we evaluated the ability of the synthetic BSA–
RuII(CO)2 complex to release CO in HeLa cells using COP-
1 to visualize changes of the CO levels by confocal micros-
copy. HeLa cells were incubated in the absence (control) or
presence of 1.5 mm BSA–RuII(CO)2, and then treated with
COP-1. Notably, we found a considerable increase in intra-
cellular fluorescence for cells incubated with BSA–RuII(CO)2
over the control (Figure 2c,d). Fluorescence intensity was
found to increase in a time-dependent manner (see CO
release movie and Figure S2 in SI). Finally, in the presence of
BSA–RuII(CO)2, cells remained viable as demonstrated both
Figure 1. CO release from HEWL–RuII(CO)2. a) Reactivity of fac-[RuL3(CO)3]
2+ complexes in
aqueous aerobic solution. b) Reaction of CORM-3 with the single-His protein HEWL and
electrospray ionization (ESI)-MS spectrum of HEWL–RuII(CO)2 under denaturing conditions.
c) ESI-MS analysis of CO release from HEWL–RuII(CO)2 at 0, 2, and 4 h in aqueous buffered
solution (PBS pH 7.4).
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by the Trypan blue exclusion test (see Figure S3 in SI) and
Hoechst33342 nuclei staining (Figure 2d).
CO and CORMs have been shown to influence the
expression levels of cytokines, matrix metalloproteinases, and
tumor necrosis factor (TNF)-a.[18–20] To confirm that CO
released from the synthetic BSA–RuII(CO)2 complex can
inhibit inflammatory responses, the expression levels of pro-
inflammatory cytokines TNF-a, interleukin (IL)-6, and IL-8,
and an anti-inflammatory cytokine, IL-10, were measured by
an enzyme-linked immunosorbent assay (ELISA). Treatment
of the adenocarcinoma cell line HeLa (Figure 3, graph a) and
Caco-2 cells (Figure 3, graph b) with 4.5 mm BSA–RuII(CO)2
for 4 h mediated the downregulation of TNF-a, IL-6, and IL-
10 in both cell lines (Figure 3 and Figure S4 in SI). IL-8 had
low expression levels in both cell lines and no significant
difference could be detected upon treatment with BSA–
RuII(CO)2. Collectively our data demonstrate that
RuII(CO)2–protein complexes can carry and release biologi-
cally functional CO in a time-dependent manner in aqueous
solution, Caco-2, and HeLa cells.
The potent bactericidal killing activity of CORM-3, which
was initially thought to be CO-mediated, has been recently
attributed to the generation of reactive oxygen species
(ROS).[21] Thus, we decided to perform a direct comparison
of the antibacterial activity of CORM-3 and BSA–RuII(CO)2
in E. coli to assess whether this would be the case for the new
CO-releasing metalloprotein. We observed that both unmodi-
fied BSA (control) and the CO-releasing BSA–RuII(CO)2
complex did not produce any significant effect on bacterial
growth (see Figure S5 in SI). These results contrast with those
elicited by CORM-3 and indicate that the new BSA–
RuII(CO)2 complex does not result in the production of
ROS species. Importantly, our data suggests that the biolog-
ical effects of the BSA–RuII(CO)2 complex may be assigned
to the released CO.
Finally, we investigated whether metalated proteins could
be used to carry and deliver CO in vivo to sites of disease by
performing a CO biodistribution study in tumor bearing mice.
Albumin is a protein known to accumulate in and be
catabolized by tumors and has been successfully used for
the delivery of drugs to tumors.[22] Balb/C athymic nude mice
were inoculated with subcutaneous murine CT-26 colon
carcinoma cells and, after tumors reached a volume of
200 mm3, were injected intravenously with 3 mgkg1 of
BSA–RuII(CO)2 or BSA alone (control). Mice were sacrificed
4 h after injection and CO levels were determined in tissues
and blood using the method described by Vreman and co-
workers.[23] We found that albumin can carry and deliver CO
in vivo with selective accumulation at the tumor (Figure 4).
Four hours after administration of BSA–RuII(CO)2, CO levels
at the tumor are threefold higher compared to that of the
blood. It must be considered that the method used for
measuring CO in tissues and blood does not distinguish
between free CO, the synthetic BSA–RuII(CO)2 complex and
CO bound to hemoglobin, which may account for the
relatively high levels of CO found in blood. We have,
however, measured the levels of carboxy hemoglobin
Figure 2. Metalation of BSA with CORM-3 and CO release in buffered
aqueous solution and in HeLa cells. a) Native MS of BSA (black) and
BSA–RuII(CO)2 (red). Peaks for BSA and BSA complex with charges
14+ to 17+ appeared at the 3800 to 5400m/z range for both species
and there is a shift of peaks for the complex toward higher m/z. b) CO
release measurement using COP-1, read from 490 to 650 nm following
excitation (lex=475 nm). Photoemission spectra were taken at 0, 10,
20, 30, 60, 90, and 120 min after the addition of 1 mm COP-1 to 1.5 mm
BSA–RuII(CO)2 in PBS pH 7.4 at 37 8C. c) Mean of total fluorescent
intensity  standard error of the mean (SEM) in HeLa cells 30 min
after addition of 1 mm COP-1 in the absence (control) or presence of
1.5 mm BSA–RuII(CO)2. Cells were pre-incubated with BSA–Ru
II(CO)2
for 30 min prior to COP-1 addition. Mean of total fluorescence
intensity is given in arbitrary units. Statistically significant differences
found after two-way ANOVA are marked as * (P<0,05). d) Confocal
microscopy images for cellular CO release in untreated (control) and
treated HeLa cells (1.5 mm BSA–RuII(CO)2). After an initial 30 min
treatment with BSA–RuII(CO)2, 1 mm COP-1 was added and, following
a 30 min incubation period, pictures were taken. In each panel, the left
picture shows nuclear staining using Hoechst33342 (blue) and the
picture to the right shows COP-1 turn-on response to CO (green).
Figure 3. Effect of CO release from BSA–RuII(CO)2 on the expression
levels of IL-6, IL-8, IL-10, and TNF-a in supernatant of adenocarcinoma
cell lines HeLa (graph a) and Caco-2 cells (graph b), measured by
ELISA. Cytokine expression was measured 4 h following treatment with
4.5 mm BSA–RuII(CO)2 (dark grey) and are presented side by side
against the untreated control (light grey). Statistically significant differ-
ences found after two-way ANOVA post-hoc test using the Bonferroni
method are marked as * (P<0,05).
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(COHb) in blood, which were found to be at basal levels (see
Figure S6 in SI) excluding any potential CO-associated
toxicity. CO accumulation at the tumor is sevenfold higher
compared to the kidney and liver, and 17 fold higher when
compared to other tissues. By performing a CO in vivo
biodistribution measurement, we were able to show that
albumin is an efficient CO carrier and specifically delivers CO
to tumor sites (Figure 4).
In this study we were able to demonstrate for the first time
that RuII(CO)2–protein complexes, formed by the reaction of
decomposition products of CORM-3 with His residues
exposed on proteins in aqueous solution, spontaneously
release CO in aqueous solution, cells, and mice. Our data
provides insight into the mechanism by which CORM-3 leads
to CO release in vivo supporting the principle of plasma
proteins as in vivo carriers of CO. By exploring CORM-3
reactivity in water, we developed and applied a ready His
metalation method that provides access to synthetic
RuII(CO)2–protein complexes. These were shown to release
CO and to influence the inhibition of inflammatory responses
as shown by the downregulation of IL-6, IL-10, and TNF-a.
Notably, by using a synthetic RuII(CO)2–albumin complex we
were able to deliver CO specifically to tumors in mice with
only basal levels of COHb. This is consistent with the
transport of CO through circulation by the RuII(CO)2–
albumin complex and specific release at the tumor site upon
accumulation. Collectively, our data not only provide new
insight on how the in vivo administration of CORM-3 results
in CO release but also suggests the use of RuII(CO)2–protein
complexes as viable alternatives for the safe and spatially
controlled delivery of therapeutic CO.
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Figure 4. CO biodistribution in blood and tissues after administration
of BSA–RuII(CO)2 in CT26 colon carcinoma bearing mice. Immunode-
ficient female BALB/c mice bearing subcutaneous CT26 colon carci-
noma cells were administered intravenously (tail vein) with 3 mgkg1
of BSA (light grey) and BSA–RuII(CO)2 (dark grey) (three mice/group).
Treatment was initiated when tumors reached a size of 200 mm3. The
animals were sacrificed 4 h after injection. Selected tissues were
isolated, homogenized, weighted, and CO levels were measured by gas
chromatography reduced compound detection (GC-RCP). Data repre-
sents pmol of CO per weighted tissue or organ as a mean of three
independent measurements (standard error). An additional mea-
surement 30 min after injection was performed using collected blood.
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